Golden
Oxford Genetics

Oxford Genetics

Oxford Genetics is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

All edits

Edits on 15 Nov 2019
Golden AI
Golden AI edited on 15 Nov 2019 5:24 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 17 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 17 Sep 2019 6:09 am
Edits made to:
Article (+6/-6 characters)

Article

On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and MericaMerica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:

Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 17 Sep 2019 6:03 am
Edits made to:
Article (+12/-12 characters)

Article

This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapygene therapy and antibody engineering. 
Jude Gomila
Jude Gomila edited on 17 Sep 2019 5:13 am
Edits made to:
Article (+10/-10 characters)

Article

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.lPerpetual. A spokesperson from Oxford Genetics made the following statement regarding the investment:

Edits on 16 Sep 2019
Golden AI
Golden AI edited on 16 Sep 2019 12:05 pm
Edits made to:
Infobox (+1 properties)
Dawson Sewell
Dawson Sewell edited on 16 Sep 2019 12:03 pm
Edits made to:
Article (+1108/-150 characters)

Article



In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.l



License agreement

...

Funding

Growth

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.l A spokesperson from Oxford Genetics made the following statement regarding the investment:

This will allow us to continue to exeed regulatory requirements and provide quality assurance for our clients. We will also add more analytical, purification and process development equipment, for instance small scale bioreactors, to enable us to fully support our clients from research up to the point of GMP bioproduction. 

Series A

On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and Merica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:

This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering. 



Edits on 15 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 15 Sep 2019 12:34 pm
Edits made to:
Article (+2/-2 characters)

Article

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the USUS and Europe, has been extended to include the Asia Pacific region.

Edits on 9 Sep 2019
Dawson Sewell
Dawson Sewell edited on 9 Sep 2019 11:16 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:39 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 11 Apr 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr 2019 6:50 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 19 Mar 2019
Golden AI
Golden AI edited on 19 Mar 2019 3:12 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 14 Nov 2018
Melanie Manipula"Approved suggestion from source: https://www.oxfordgenetics.com/"
Melanie Manipula approved a suggestion from Golden's AI on 14 Nov 2018 9:08 pm
Edits on 14 Nov 2018
Jude Gomila"Approved suggestion from source: https://www.oxfordgenetics.com/"
Jude Gomila approved a suggestion from Golden's AI on 14 Nov 2018 3:13 am
Edits made to:
Infobox (+1 properties)
Edits on 26 Oct 2018
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 26 Oct 2018 8:21 pm
Edits made to:
Article (+18/-18 characters)

Article

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.lInvesco Perpetua.l

Edits on 29 Sep 2018
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 29 Sep 2018 12:29 am
Edits made to:
Article (+6/-6 characters)

Article

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPRCRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 28 Sep 2018 11:04 pm
Edits made to:
Article (+6/-6 characters)

Article

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and EuropeEurope, has been extended to include the Asia Pacific region.

Carla Faraguna
Carla Faraguna edited on 28 Sep 2018 8:29 pm
Edits made to:
Infobox (+3 properties)
Description (+160 characters)
Article (+687 characters)
Categories (+1 topics)
Related Topics (+2 topics)
Topic thumbnail

Oxford Genetics

Oxford Genetics is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

Article

Oxford Genetics is a leading synthetic biology company focused on developing technologies to associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.



In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetua.l

...

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.

Infobox

Categories

Related Topics

Edits on 21 Apr 2018
Melanie Manipula
Melanie Manipula edited on 21 Apr 2018 12:07 am
Edits made to:
Topic thumbnail

Oxford Genetics

Oxford Genetics is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

Melanie Manipula"Initial topic creation"
Melanie Manipula created this topic on 20 Apr 2018 11:56 pm
Edits made to:
Description
Academic papers
People
Further reading
Documentaries, videos and podcasts
Companies
Products
Topic thumbnail

 Oxford Genetics

Oxford Genetics is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

No more activity to show.